Key highlights

  • Clover Corporation Ltd (ASX:CLV) has a fully franked final dividend of 1.25 cents per share with an ex-dividend date of 20 October 2026 and payment on 19 November 2026.
  • The 22 September 2026 announcement reports record FY26 revenue of $97.4 million, up 13%, and NPAT of $10.5 million, up 50%.
  • Second-half revenue was $53.3 million compared with $44.1 million in the first half.

Clover Corporation Ltd (ASX:CLV) makes nutritional oils and powders, including ARA powders, and it owns Melody Dairies. As at 19 October 2026, it has a fully franked final dividend of 1.25 cents per share that goes ex-dividend on 20 October 2026. In an ASX announcement dated 22 September 2026, the company reported its results for the year ended 31 July 2026.

About the company

Clover’s vertical integration includes a crude tuna oil facility in Ecuador, which the announcement calls a secure and competitively priced source of supply, and Melody Dairies, which achieved higher production volumes and lower unit costs. The company is commercialising a flowable choline powder, CholineXcel, with customer trials started and intellectual property filed.

Upcoming dividend details

Dividend type

Final

Amount per share

$0.0125 (1.25 cents)

Franking

100% franked

Ex-dividend date

20 October 2026

Payment date

19 November 2026

Last price in the table

$1.03

The Board declared a fully franked final dividend of 1.25 cents per share for FY26. Shareholders need to hold shares before the ex-dividend date to be eligible for the dividend.

FY26 results

Revenue was a record $97.4 million, up 13% and ahead of guidance. Second-half revenue of $53.3 million was 10% higher than the same period a year earlier. Net profit after tax was $10.5 million, up 50% from $7.0 million. The company attributes the result to demand for newer products, innovation and ARA powders carrying higher margin, and to improved operating performance at Melody Dairies.

Strategy and supply chain

The announcement ties the improved margin to investment in supply chain quality and security and in new products. It says it has broadened market reach through an expanded distribution model and continues to build a more diversified earnings base.

The result by half-year is worth noting: first-half revenue was $44.1 million and second-half revenue was $53.3 million, a rise of 10% on the second half of the previous year. The company says the improvement in margin comes from supply chain investment and new products, with Melody Dairies achieving higher volumes and lower unit costs and the Ecuador crude tuna oil facility supplying oil at competitive cost.

The announcement also covers strategic progress, including the commercialisation of CholineXcel, a unique flowable powder, with customer trials started and intellectual property filed. The chief executive is quoted describing the year as one of disciplined execution of the core business while serving existing and new customers. The announcement gives no guidance for FY27 in the part reviewed.

How the dividend timetable works

The ex-dividend date of 20 October 2026 is the first trading day on which shares change hands without the right to the upcoming dividend of 1.25 cents per share. Shares bought before that date carry the entitlement, subject to the record date and settlement timing, while shares bought on or after it do not. Payment follows on 19 November 2026, 30 days after the ex-dividend date. The ex-dividend date falls 1 days after 19 October.

The dividend is fully franked, which means franking credits equal to the Australian company tax paid on the underlying profit are attached. How much those credits are worth depends on each shareholder’s own tax position, which this article does not assess.

A dividend is a distribution of profit that the board decides to pay, and the amounts quoted are per share. The total cash paid depends on the number of shares on issue at the record date, which can change if a company issues new shares or repurchases existing ones. Dates and amounts can change if the company announces an update.

Factors shareholders may weigh

The result depends on demand from a limited number of customers for specialised nutritional ingredients, and on raw material supply and pricing. CholineXcel is at an early stage, with customer trials only recently begun.

Revenue and profit were records in FY26, but results in future years may differ, and the dividend is a board decision made each period.

What’s next

The final dividend goes ex on 20 October 2026 and is paid on 19 November 2026. The company will continue commercialising CholineXcel and developing its newer products.